HCA Healthcare (HCA) Maintained at Buy by Jefferies, April 2026

Jefferies maintained its Buy rating on HCA Healthcare (HCA) on April 24, 2026, but cut its price target to $525 from $590. The Nashville-based hospital operator trades at $432.50, down 8.76% today amid broader healthcare sector pressure. With a market cap of $96.7 billion and 320,000 employees across 182 hospitals, HCA remains a dominant player in U.S. medical care facilities. The analyst action reflects cautious optimism despite near-term headwinds affecting the healthcare industry.

Jefferies Maintains Buy Rating on HCA Healthcare

Price Target Reduction

Jefferies lowered its price target to $525 from $590, signaling a more cautious stance on near-term valuation. The $65 reduction reflects concerns about operational headwinds and market dynamics. At the current price of $432.50, the stock sits 22.6% below the new target, suggesting upside potential. However, the lower target indicates analysts expect slower near-term momentum than previously anticipated.

Rating Rationale

Despite the price target cut, Jefferies kept its Buy rating intact, showing confidence in HCA’s long-term fundamentals. The company operates 182 hospitals, 125 freestanding surgery centers, and 21 endoscopy centers across 20 states and England. HCA generated strong earnings with an EPS of $28.35 and maintains a PE ratio of 15.26, below historical averages. The maintained rating suggests the analyst believes current weakness presents a buying opportunity for long-term investors.

HCA Healthcare Stock Performance and Valuation

Recent Price Action

HCA shares fell $41.53 today, closing at $432.50 after trading between $422.23 and $451.57. The stock is down 10.95% over one month and 8.76% year-to-date, underperforming the broader market. However, HCA has gained 26.68% over the past year, reflecting strong long-term performance. The 50-day moving average sits at $508.70, indicating the stock trades well below its recent trend.

Valuation Metrics

With a PE ratio of 15.26 and price-to-sales ratio of 1.41, HCA trades at reasonable valuations relative to healthcare peers. The company generated $327.68 in revenue per share and $29.40 in net income per share trailing twelve months. Free cash flow per share reached $33.34, demonstrating strong cash generation. Operating margins of 15.83% and net margins of 8.97% show solid profitability despite industry pressures.

Analyst Consensus and Meyka AI Grade

Broad Analyst Support

Jefferies’ maintained rating aligns with strong analyst consensus. Among 32 tracked analysts, 25 rate HCA as Buy, 6 recommend Hold, and only 1 suggests Sell. This consensus score of 3.0 reflects overwhelming bullish sentiment. The broad support underscores confidence in HCA’s market position and growth prospects despite current headwinds. Analyst price targets cluster around the $525 level, suggesting limited downside risk.

Meyka AI Grade Assessment

Meyka AI rates HCA Healthcare with a grade of B+, indicating a strong buy recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 77.61 out of 100 reflects solid fundamentals and growth potential. These grades are not guaranteed and we are not financial advisors.

Financial Growth and Forward Outlook

Strong Earnings Expansion

HCA delivered impressive financial growth in 2025. Net income grew 17.78%, while earnings per share surged 28.51% due to share buybacks. Revenue expanded 7.08%, and operating income climbed 13.44%. Free cash flow growth accelerated 36.41%, demonstrating improved capital efficiency. These metrics show HCA is expanding profitably despite healthcare industry challenges. The company’s ability to grow earnings faster than revenue reflects operational leverage and cost discipline.

Forward Guidance and Forecasts

Meyka AI forecasts HCA stock reaching $468.65 by year-end 2026, $573.39 by 2029, and $677.75 by 2031. These projections assume continued earnings growth and market recovery. The company’s dividend yield of 0.62% and payout ratio of 10.01% provide flexibility for future increases. With earnings announcements scheduled for July 23, 2026, investors will gain clarity on management’s outlook and operational trends.

Final Thoughts

Jefferies’ maintained Buy rating on HCA Healthcare reflects confidence in the company’s long-term value despite near-term challenges. The price target reduction to $525 acknowledges current market pressures but still implies 21% upside from current levels. HCA’s strong fundamentals—including 15.26x PE ratio, 36% free cash flow growth, and dominant market position—support the bullish stance. With 25 of 32 analysts rating the stock Buy and Meyka AI assigning a B+ grade, HCA appears well-positioned for recovery. Investors should monitor Q2 earnings in July for confirmation of management’s operational trajectory and capital allocation plans.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.